Subject:
- Active Sustance: Efgartigimod alfa
- Name: Vyvgart®
- Therapeutic area: Myasthenia Gravis
- Pharmaceutical company: Argenx Germany GmbH
Time table:
- Start: 01.09.2022
- Final decision by G-BA: 16.02.2023
Final decision:
- Hint for a considerable additional benefit